|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Men with the rs1045531 AA genotype of PSCA were at higher risk for prostate cancer.
|
21497359 |
2011 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Men with the rs1045531 AC genotype of prostate stem cell antigen were at higher risk of prostate cancer in Chinese patients undergoing prostate biopsy.
|
29332451 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data confirms that PSCA-CAR T cells may be developed for treatment of prostate cancer.
|
24438073 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSCA may therefore be a useful predictor of tumor biology and a useful target of immunotherapy against prostate cancer.
|
12172427 |
2002 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), human kallikrein 2 (hK2), prostate stem cell antigen (PSCA), and differential display code 3 (DD3) in 2215 LNs isolated from 120 patients with localized prostate cancer were assessed by fully quantitative real-time RT-PCR.
|
21600799 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-PCR PSCA positivity in peripheral blood may be a potential modality for molecular staging of PCa.
|
17645609 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate stem cell antigen (PSCA) is emerging as an important diagnostic marker and therapeutic target in prostate cancer.
|
12351697 |
2002 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that loss of AR responsiveness to the PSCA promoter may result in the induction of an androgen-independent mechanism, that is, the insulin-like growth factor-binding protein 2 signalling pathway-a key event in the development of hormone-independent prostate cancer-and this may increase the metastatic potential.
|
23397433 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show the construction of a molecular imaging probe comprising a humanized scFv fragment recognizing PSCA genetically fused to an engineered version of the human DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT), the SNAP-tag, enabling specific covalent coupling to various fluorophores for diagnosis of PCa.
|
28667390 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate stem cell antigen (PSCA), a homologue of the Ly-6/Thy-1 family of cell surface antigens, is expressed by a majority of human prostate cancers and is a promising target for prostate cancer immunotherapy.
|
11406532 |
2001 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
|
26477693 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate stem cell antigen (PSCA) has been suggested as biomarker and therapeutic target for prostate cancer.
|
28903367 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we define immunogenic peptides of PSCA which are recognized by circulating CD8(+) T cells from prostate cancer patients and able to activate CTLs in vitro.
|
12402309 |
2002 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Messenger RNA and protein expression levels for integrin α(ν) β(3), neurotensin receptor 1 (NTSR1), prostate specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA) were measured in LNCaP, C4-2, and PC-3 human prostate cancer cell lines and in murine xenografts using quantitative reverse transcriptase polymerase chain reaction, flow cytometry, and immunohistochemistry.
|
21748756 |
2012 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BPH patients with RT-PCR PSCA positive were significantly more likely to develop prostate cancer (OR = 16, 95% CI = 8.1-31.6, P < 0.001).
|
25698533 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate stem cell antigen (PSCA) has been considered a potentially worthwhile target for prostate cancer therapy with its overexpression in both androgen-dependent and androgen-independent prostate cancers.
|
23701419 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo <i>s</i>pecificity for PSCA-expressing tumor cells and biodistribution of the dual-modality tracer were evaluated in a prostate cancer xenograft model and compared with single-labeled <sup>124</sup>I-A2cDb.
|
29602820 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a functional chimeric TCR against PSCA for treatment of PCa.
|
17492652 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to prostate-specific antigen, prostate-specific membrane antigen and human kallikrein-2, the recently identified prostate stem cell antigen may also provide us with a new tool for the diagnosis and treatment of prostate cancer.
|
10325497 |
1999 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ-confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy.
|
16015594 |
2005 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations emphasize and extend the potential of the human HSP70 gene as adjuvant for DNA vaccines, and the vaccine based on PSCA and HSP70 is of potential value for treating prostate cancer.
|
17595048 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate stem cell antigen gene was originally identified through an analysis of genes upregulated in the human prostate cancer LAPC-4 xenograft model.
|
24320701 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we show that the UniCAR platform can be used to efficiently target solid cancers <i>in vitro</i> and <i>in vivo</i> using a pre-clinical prostate cancer model which overexpresses prostate stem cell antigen (PSCA).
|
29123951 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the <i>cpe</i> and <i>PSCA</i> genes affects the PC3 cell death so it could be a suitable candidate for further researches in prostate cancer vaccine development.
|
31478797 |
2020 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations suggest that the formulation of the bivalent prostate cancer vaccine (Ad<sub>5</sub>-PSA+PSCA) with surgifoam bypasses the neutralizing antibody response, thus allowing multiple boosting.
|
28939158 |
2017 |